Integrated Approaches to Food Allergen and Allergy Risk Management
iFAAM
1 other identifier
interventional
72
1 country
1
Brief Summary
Patients with history of a food allergy to hazelnut, walnut or celeriac will undergo food provocation with a dose of the allergenic food to which 5% of the respective food allergic population (ED05) has been calculated to respond with allergic reactions (single shot study). In patients with a hazelnut or peanut allergy a double-blind placebo controlled food challenge with cookies containing either placebo or hazelnut and peanut respectively will be performed to determine threshold levels eliciting an allergic reaction. The results for threshold levels determined by cookie matrix will be compared to the results gained from the EuroPrevall project (matrix comparison study). In patients with a walnut allergy double-blind placebo controlled provocation with walnut will be combined with the intake of proton pump inhibitor (PPI) or with placebo to assess the impact of PPI on the threshold level and on the clinical manifestation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Nov 2014
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2014
CompletedFirst Submitted
Initial submission to the registry
November 11, 2014
CompletedFirst Posted
Study publicly available on registry
November 20, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2017
CompletedMay 11, 2017
May 1, 2017
2.3 years
November 11, 2014
May 10, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
numbers of patients reacting to ED05 in hazelnut, walnut, celeriac allergy
November 2014 to February 2017, up to 27 months
Secondary Outcomes (2)
numbers of patients reacting to a defined dose of peanut and hazelnut in titrated challenges
November 2014 to February 2017, up to 27 months
Change in the threshold dose of walnut that induces an allergic reaction after the intake of therapeutic doses of omeprazole Change in the severity of walnut allergy after the intake of therapeutic doses of omeprazole
February 2015 to February 2017, up to 27 months
Study Arms (1)
food provocation
EXPERIMENTALopen and placebo-controlled food challenges
Interventions
Eligibility Criteria
You may qualify if:
- Signed informed consent
- For single shot study: history of a hazelnut, walnut, celeriac allergy due to an unequivocal accidental exposure with typical acute allergic reaction within the preceding 2 years and positive allergen-specific skin prick test/specific Immunoglobulin E or recent positive oral food challenge with hazel, walnut or celeriac within previous 2 years in children \<16 years, but no time limit specified for adults
- For matrix comparison study: history of peanut or hazelnut allergy
- For walnut/PPI study: history of walnut allergy. The minimum age for this study is 18 years
You may not qualify if:
- Severe disease (heart, liver, kidney), acute febrile infection
- Intake of Ketotifen (past 2 weeks), corticosteroids (past 2 weeks), histamine-1-receptor blocker (past 3 days apart first generation past 7 days)
- Anaphylactic reaction (past 4 weeks)
- Uncontrolled bronchial asthma, forced expiratory volume \< 70% predicted
- Pregnancy
- Acute infection or allergy
- Uncontrolled atopic dermatitis
- Chronic urticaria
- Mastocytosis
- Uncontrolled hypertension
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Zurichlead
- Cork University Hospitalcollaborator
- Charite University, Berlin, Germanycollaborator
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)collaborator
- University of Nebraska Lincolncollaborator
- Region Hovedstadens Apotekcollaborator
- Servicio Madrileño de Salud, Madrid, Spaincollaborator
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnementcollaborator
Study Sites (1)
Allergy Unit, Department of Dermatology, University Hospital
Zurich, 8091, Switzerland
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Clare Mills, Coordinator
University Manchester
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 11, 2014
First Posted
November 20, 2014
Study Start
November 1, 2014
Primary Completion
February 1, 2017
Study Completion
February 1, 2017
Last Updated
May 11, 2017
Record last verified: 2017-05